ArticleJHLT open2026
Mapping acute lung allograft dysfunction of unknown cause after lung transplantation: Insights from clinical and radiological patterns.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung allograft dysfunction (ALAD) is a recently defined post-transplant clinical entity characterized by acute, potentially reversible graft dysfunction. The aim of this study was to describe the clinical and radiological features of ALAD in which no identifiable underlying cause could be recognized, hereafter referred to as idiopathic ALAD (i-ALAD). Methods: Among all bronchoscopies with bronchoalveolar lavage and transbronchial lung biopsy performed in a single-center cohort of lung transplant recipients between 2013 and 2024 ( Results: Among 158 lung transplant recipients, 20 cases of i-ALAD were identified, corresponding to an incidence of 12.4%. ALAD was reversible in most patients, although 2 progressed to chronic lung allograft dysfunction (CLAD). Six patients (30%) met criteria for baseline lung allograft dysfunction (BLAD), and 6 had a history of recurrent ACR. HRCT most frequently demonstrated bronchial wall thickening (85%), smooth interlobular septal thickening, and pulmonary micronodules (80%), with characteristic lobar distribution patterns. Compared with ACR, i-ALAD was associated with a significantly higher prevalence of bronchiectasis/bronchiolectasis, air trapping, and pleural effusion. Conclusions: ALAD is a relatively frequent and potentially reversible complication after lung transplantation but may represent a risk factor for subsequent CLAD development. Distinctive HRCT features may assist in identifying ALAD of unknown cause and stratifying patients according to the risk of disease progression. Prospective, multicenter studies are warranted to validate these findings and further refine the clinical and radiological characterization of i-ALAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.